摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-N-benzoylcysteine

中文名称
——
中文别名
——
英文名称
D-N-benzoylcysteine
英文别名
N-benzoylcysteine;(S)-2-benzamido-3-mercaptopropanoic acid;(2S)-2-benzamido-3-sulfanylpropanoic acid
D-N-benzoylcysteine化学式
CAS
——
化学式
C10H11NO3S
mdl
——
分子量
225.268
InChiKey
LJWSDBHOEIBWJY-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    67.4
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    N,N'-bis(benzoyl)-D-cystine 在 sodium tetrahydroborate 作用下, 以 乙醇 为溶剂, 生成 D-N-benzoylcysteine
    参考文献:
    名称:
    Dynamic Combinatorial Mass Spectrometry Leads to Metallo-β-lactamase Inhibitors
    摘要:
    The use of protein ESI mass spectrometry under non-denaturing conditions to analyze a dynamic combinatorial library of thiols/disulfides with the BcII metallo-beta-lactamase enabled the rapid identification of an inhibitor with a K-i of < 1 mu M. The study exemplifies the utility of protein-MS for screening dynamic mixtures of potential enzyme-inhibitors.
    DOI:
    10.1021/jm070866g
  • 作为试剂:
    描述:
    参考文献:
    名称:
    使用N-苯甲酰半胱氨酸作为手性配体用硼氢化锂不对称还原烷基芳基酮
    摘要:
    N-苯甲酰基半胱氨酸是一种具有硫供体原子的手性配体,被发现在用硼氢化锂(高达 92-93%ee)对映选择性还原烷基芳基酮方面非常有效。
    DOI:
    10.1246/cl.1984.251
点击查看最新优质反应信息

文献信息

  • NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT
    申请人:Weiner Carl P.
    公开号:US20090318454A1
    公开(公告)日:2009-12-24
    Formula 1 is an antioxidant compound, wherein R, R1, or D is an antioxidant substituent; R and D are each independently selected from hydrogen or groups containing cysteine, thiols, disulfides, amino acids, amines, amides, or carboxylic acids; when one of R or D is hydrogen, the other includes a thiol, disulfide, or carboxylic acid; A is CO, SO, SO 2 , or C═S; E is one or more ring groups which are aromatic, carbocyclic, and/or heterocyclic 5, 6 and 7 membered rings being mono, bi, tri, tetra, penta, hexa, hepta or octa cyclic fused rings that are substituted or unsubstituted, each heterocyclic ring can include hetero atoms chosen from to O, S, N, Se, or P; each R1 is at a para, meta, and/or ortho position; n is 1, 2, 3, 4, or 5 for each ring; and each R1 is hydrogen or an antioxidant substituent.
    Formula 1是一种抗氧化化合物,其中R,R1或D是抗氧化剂取代基;R和D分别独立选择自氢或含有半胱氨酸,巯基,二硫键,氨基酸,胺,酰胺或羧酸的基团;当R或D中的一个是氢时,另一个包括巯基,二硫键或羧酸;A是CO,SO,SO2或C═S;E是一个或多个芳香族,碳环或杂环的环基团,其中5, 6和7个成员环可以是单环,双环,三环,四环,五环,六环,七环或八环的融合环,可以是取代或未取代的,每个杂环可以包含从O,S,N,Se或P选择的杂原子;每个R1位于对位,间位和/或邻位;n对于每个环是1, 2, 3, 4或5;每个R1是氢或抗氧化剂取代基。
  • Urea derivative, process for producing the same, and use
    申请人:Kubo Keiji
    公开号:US20070093501A1
    公开(公告)日:2007-04-26
    The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.
    本发明提供一种尿素衍生物或其盐,其作为治疗血栓症的治疗剂是有用的。该衍生物由公式(I)表示:其中,Cy是芳香族羟基烃基或芳香族杂环基,可以被取代;R1是氢原子或可以被取代的碳氢基团;V是-C(O)-,-S(O)-或-S(O)2-;W是-N(R2)-,-O-或键(其中R2是氢原子或可以被取代的碳氢基团);X是可以被取代的烷基;Y是-C(O)-,-S(O)-或-S(O)2-;Z是键,可以被取代的链烃基团或-N═;环A是非芳香族含氮杂环环,可以被取代;环B是含氮杂环环,可以被取代;而[化学式2]都是单键或双键;但是,R1可以与R2连接形成非芳香族含氮杂环环,而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
  • Cyclic peptides and use thereof
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:EP0528312A2
    公开(公告)日:1993-02-24
    Disclosed are (1) a cyclic hexapeptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient.
    公开了 (1) 由式 [I] 表示的环六肽或其盐: 其中 X 和 Y 分别代表 a-氨基酸残基,A 代表 D-酸性-a-氨基酸残基,B 代表中性-a-氨基酸残基,C 代表 L-a-氨基酸残基,D 代表具有芳香环基的 D-a-氨基酸残基;以及 (2) 一种药物组合物,其活性成分包含式 [I] 所代表的肽或其药学上可接受的盐。
  • Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:EP0626174A2
    公开(公告)日:1994-11-30
    Compounds having antagonistic activity on endothelin receptors can be effectively used for prophylaxis and/or treatment of hypofunction of organs which occurs in their surgery or transplant.
    对内皮素受体具有拮抗活性的化合物可有效用于预防和/或治疗器官移植手术中出现的器官功能减退。
  • Sustained-release preparation of anti-endothelin substance
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP0647449A1
    公开(公告)日:1995-04-12
    A sustained-release preparation containing an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.
    一种含有抗内皮素物质和生物可降解聚合物的缓释制剂。 本发明的缓释制剂能持续释放抗内皮素物质,可用于治疗内皮素相关疾病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐